Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors

Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, respectively....

詳細記述

保存先:
書誌詳細
出版年:Cancer Res
主要な著者: Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M., Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E., Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J., Bahcall, Magda, Oxnard, Geoffrey R., Eck, Michael J., Jänne, Pasi A.
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596996/
https://ncbi.nlm.nih.gov/pubmed/28363995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-3404
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料